ALISO VIEJO, Calif., July 30, 2015 /PRNewswire/ — Sentrian, the Remote Patient Intelligence™ company aspiring to eliminate all preventable hospitalization, recently received confirmation from the Food & Drug Administration (FDA) that its Remote Patient Intelligence (RPI) solution meets the definition of a “medical device” for which the FDA intends to exercise “Enforcement Discretion.”
The designation identifies medical devices that “are not subject to further FDA regulatory requirements at this time” and clears the way for Sentrian to immediately begin marketing its RPI solution broadly in the U.S.
On February 9, 2015 the FDA released a Mobile Medical Applications report announcing it would take a tailored, risk-based approach to regulating medical devices, with a focus on the small subset of technologies that meet the regulatory definition of “device.” For the many mobile and cloud-based applications that the FDA deems a “device” but which pose minimal risk to patients and consumers, the agency will exercise enforcement discretion and will not expect manufacturers to submit premarket review applications or register their products.
“We are encouraged by the FDA’s well-balanced approach to nurturing innovation in mHealth while ensuring patient safety in their assessment process,” said Dean Sawyer, Co-Founder and CEO of Sentrian. “The FDA’s decision enhances our ability to provide value to patients and care providers managing chronic conditions such as heart disease, complex diabetes, and COPD by increasing our product development speed and agility. It also affirms Sentrian’s mission to improve the quality of life for the patients we serve.”
Dr. Jack Kreindler, Sentrian’s Founder and Chief Medical Officer, added, “This is a landmark for Sentrian and the industry allowing unprecedented speed to continually deliver what patients and providers need. Internally we continue to build our technology to exceed the quality, security, privacy and safety management standards required for tightly regulated medical devices. This gives our clients and patients the added confidence they demand and prepares us for the near future when algorithmic decision support will steer personalized interventions, in advance of traditional evidence determining what’s best for our patients.”
Sentrian RPI is already being used by patients enrolled in adaptive research studies with Anthem’s Caremore Medicare Advantage Health Plan and other healthcare organizations. Sentrian’s cloud-based technology leverages the revolution in biometric devices and machine learning with the intention of detecting actionable health deterioration early and with higher accuracy, helping to reduce preventable hospitalization in patients with complex chronic disease.
Sentrian™, the first Remote Patient Intelligence™ Company, aspires to eliminate all preventable hospitalization by leveraging the revolution in remote biosensors and machine learning to detect patient deterioration early, before it becomes acute. Sentrian’s value proposition to health care organizations is to provide a cloud-based remote patient monitoring and analytics platform intended to dramatically reduce preventable hospital admissions, increase the efficiency and effectiveness of care teams and improve quality metrics such as HEDIS and Star ratings. The Sentrian platform is designed to seamlessly integrate with existing healthcare information systems and clinical workflows, facilitating adoption. Sentrian is the sole winner of the American Telemedicine Association’s 2015 President’s Award for Innovation in Remote Health Care. Find us at www.sentrian.com, on Twitter and LinkedIn.